Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Endo Tries Its Luck With The Irish Through $1.6 Billion Paladin Acquisition

This article was originally published in The Pink Sheet Daily

Executive Summary

The specialty pharma will expand its global footprint, continue its re-transformation into a specialty pharma business, and gain an appealing new tax rate through the acquisition of Montreal-based Paladin Labs.

Advertisement

Related Content

Elan’s Saga Comes To A Close With Perrigo’s $8.6 Billion Bid
Endo’s Next Chapter Will Be Led By CEO De Silva

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS075115

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel